Results 71 to 80 of about 1,064,284 (379)
Original Effective, Safe Technique of Obtaining Platelet Rich Plasma by Centrifugation of the Blood Plasma in Modified Syringe Containers [PDF]
The aim: to develop, substantiate an effective and safe technology for producing PRP (platelet rich plasma). To quantify the substrate based on the recommended centrifugation protocols.Materials and methods: the effectiveness of the original harvesting ...
Atanasov, D. (Dmitro) +1 more
core +3 more sources
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa +14 more
wiley +1 more source
Presence of platelet-activating factor-acetylhydrolase in milk
Human milk contains numerous factors such as immunoglobulins, lactoferrin, lysozyme, macrophages, etc., which serve an immunoprotective role. Platelet-activating factor (PAF) is one of the most proinflammatory agents thus far described.
M Furukawa +3 more
doaj +1 more source
Imperial strategy of cancer cells through mitochondrial transfer
Cangkrama et al. demonstrated that cancer cells donate their mitochondria to fibroblasts through mitochondrial transfer, reprogramming them into ‘MitoCAF’. Likewise, our group has identified mitochondrial transfer from cancer cells to tumor infiltrating lymphocytes, resulting in mitochondrial ‘hijack’ and impaired antitumor immunity.
Takamasa Ishino, Yosuke Togashi
wiley +1 more source
Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-Lack of association between activating AKT mutation and AKT inhibition-derived efficacy [PDF]
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced ...
Boix, Oliver +14 more
core +3 more sources
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
The platelet aggregation and 5-HT release by washed platelet from coronary heart disease patients following platelet activating factor (PAF) treatment were detected by turbidimetry and O-phthalaldehyde assay.
Damin Huang +10 more
doaj +1 more source
Background Irritable Bowel Syndrome (IBS) is a widespread disease with variable symptoms that have an important impact on the quality of life. Despite the prevalence of IBS, its etiology and pathophysiology are still to be fully understood, but immune ...
Mattia Cappelletti +6 more
doaj +1 more source
Specific binding of phospholipid platelet-activating factor by human platelets.
The binding of the phospholipid platelet-activating factor 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC) to washed human platelets was more than 80% complete within 2 min, which coincided with the time of initiation of platelet ...
F. Valone +3 more
semanticscholar +1 more source
Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior +5 more
wiley +1 more source

